The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Rural Ohio System Awaits $80M in Delayed CMS Payments

Memorial Health System, based in Marietta, Ohio, is waiting on roughly $80 million in Medicaid supplemental payments that depend on federal sign-off, CEO Scott Cantley told Becker's Hospital Review. About $60 million of that is tied to the Ohio Rural Tax Pilot Program, a state-directed payment program described as the first in Ohio built specifically for rural hospitals. It has awaited CMS approval for months.

State-directed payments let states route extra Medicaid dollars to providers, often funded through provider taxes or assessments, but the money cannot flow until CMS approves the arrangement. For rural systems operating on thin margins, that approval timeline is more than a paperwork delay. It affects cash flow, staffing, and the ability to keep services open in communities with few alternatives.

Memorial's situation shows how dependent rural providers have become on these programs, and how exposed they are when federal review stalls. The holdup arrives as rural hospitals nationwide face mounting financial pressure and scrutiny over how supplemental Medicaid funding is structured.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.